The study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read More
Guardant Health is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
Read More
The acquisition of Resolution Bioscience complements and expands Agilent’s capabilities in NGS-based cancer diagnostics.
Read More
Developing technology ushers in a new era in precision oncology.
Read More
The FDA has approved two comprehensive genomic profiling liquid biopsy tests for use in supporting doctors with their treatment decision-making.
Read More